Michael Edward Szperka

Array ( [id] => 16704388 [patent_doc_number] => 10954308 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Antibodies to ticagrelor and methods of use [patent_app_type] => utility [patent_app_number] => 16/035954 [patent_app_country] => US [patent_app_date] => 2018-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 26 [patent_no_of_words] => 24734 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16035954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15163347 [patent_doc_number] => 10487154 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-26 [patent_title] => Antibodies to ticagrelor and methods of use [patent_app_type] => utility [patent_app_number] => 16/035964 [patent_app_country] => US [patent_app_date] => 2018-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 24699 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16035964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13522047 [patent_doc_number] => 20180312566 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => Fc FUSION HIGH AFFINITY IgE RECEPTOR ALPHA-CHAIN [patent_app_type] => utility [patent_app_number] => 16/034648 [patent_app_country] => US [patent_app_date] => 2018-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5387 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16034648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18717880 [patent_doc_number] => 11795211 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-24 [patent_title] => Rapid elicitation of broadly neutralizing antibodies to HIV Env [patent_app_type] => utility [patent_app_number] => 16/630768 [patent_app_country] => US [patent_app_date] => 2018-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 34 [patent_no_of_words] => 74036 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16630768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885418 [patent_doc_number] => 20210171613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => CLOSTRIDIUM DIFFICILE-SPECIFIC ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/630714 [patent_app_country] => US [patent_app_date] => 2018-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13801 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16630714 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13537255 [patent_doc_number] => 20180320174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING LUPUS [patent_app_type] => utility [patent_app_number] => 16/030185 [patent_app_country] => US [patent_app_date] => 2018-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21495 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16030185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18620442 [patent_doc_number] => 11753470 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-12 [patent_title] => Bispecific anti PD1-anti TIM3 antibodies [patent_app_type] => utility [patent_app_number] => 16/628937 [patent_app_country] => US [patent_app_date] => 2018-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 22 [patent_no_of_words] => 22442 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 197 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16628937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16016095 [patent_doc_number] => 20200182890 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => Binding Molecule Activating FXII [patent_app_type] => utility [patent_app_number] => 16/622064 [patent_app_country] => US [patent_app_date] => 2018-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16622064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19013053 [patent_doc_number] => 11919969 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-05 [patent_title] => Bispecific antibodies for factor IX and factor X [patent_app_type] => utility [patent_app_number] => 16/625109 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 35288 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 291 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16625109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16093575 [patent_doc_number] => 20200200774 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => METHODS FOR IDENTIFYING WHETHER PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE (ADHF) EXHIBIT A HYPERCOAGULABLE STATE [patent_app_type] => utility [patent_app_number] => 16/624974 [patent_app_country] => US [patent_app_date] => 2018-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9900 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16624974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866289 [patent_doc_number] => 20200140548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => METHOD FOR THE TREATMENT OF IMMUNE THROMBOCYTOPENIA [patent_app_type] => utility [patent_app_number] => 16/622658 [patent_app_country] => US [patent_app_date] => 2018-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21178 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16622658 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13565923 [patent_doc_number] => 20180334509 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-22 [patent_title] => MONOCLONAL ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR (TFPI) [patent_app_type] => utility [patent_app_number] => 15/997481 [patent_app_country] => US [patent_app_date] => 2018-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15306 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15997481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16569154 [patent_doc_number] => 20210008160 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => POLYPEPTIDES BINDING ADAMTS5, MMP13 AND AGGRECAN [patent_app_type] => utility [patent_app_number] => 16/617846 [patent_app_country] => US [patent_app_date] => 2018-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37664 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16617846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778039 [patent_doc_number] => 20210115117 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2021-04-22 [patent_title] => AGGRECAN BINDING IMMUNOGLOBULINS [patent_app_type] => utility [patent_app_number] => 16/617025 [patent_app_country] => US [patent_app_date] => 2018-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50562 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -87 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16617025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778039 [patent_doc_number] => 20210115117 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2021-04-22 [patent_title] => AGGRECAN BINDING IMMUNOGLOBULINS [patent_app_type] => utility [patent_app_number] => 16/617025 [patent_app_country] => US [patent_app_date] => 2018-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50562 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -87 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16617025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778039 [patent_doc_number] => 20210115117 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2021-04-22 [patent_title] => AGGRECAN BINDING IMMUNOGLOBULINS [patent_app_type] => utility [patent_app_number] => 16/617025 [patent_app_country] => US [patent_app_date] => 2018-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50562 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -87 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16617025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13618861 [patent_doc_number] => 20180360982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => FACTOR VIII CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/991629 [patent_app_country] => US [patent_app_date] => 2018-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39824 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15991629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17698287 [patent_doc_number] => 11372008 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-28 [patent_title] => Blood factor monitoring assay and uses thereof [patent_app_type] => utility [patent_app_number] => 15/979349 [patent_app_country] => US [patent_app_date] => 2018-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 29 [patent_no_of_words] => 30756 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 238 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15979349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16351819 [patent_doc_number] => 10792311 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-06 [patent_title] => Stimulation of ovarian follicle development and oocyte maturation [patent_app_type] => utility [patent_app_number] => 15/978947 [patent_app_country] => US [patent_app_date] => 2018-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 32 [patent_no_of_words] => 15569 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15978947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14294493 [patent_doc_number] => 10287363 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-14 [patent_title] => Thrombin-binding antibody molecules and uses thereof [patent_app_type] => utility [patent_app_number] => 15/976512 [patent_app_country] => US [patent_app_date] => 2018-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 26 [patent_no_of_words] => 9276 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15976512 [rel_patent_id] =>[rel_patent_doc_number] =>)